Our Mission

The scientific mission of the MGH-Harvard-CO SCORE (U54MH118919) is to identify stress and immune pathway abnormalities, beginning in fetal development, that have adverse consequences for sex differences in brain circuitry implicated in major depressive disorder (MDD), autonomic and neurovascular dysfunction, and risk for cardiovascular disease (CVD). We are facilitating transdisciplinary, translational collaborations among basic and clinical investigators to enhance our understanding of sex differences in the comorbidity of MDD and CVD and develop a novel non-invasive neuromodulation therapy targeted to the neural-cardiac interface in a sex-selective manner. Further, we aim to serve as an interdisciplinary resource to train and disseminate findings about sex differences in MDD, autonomic dysregulation, and cardiovascular risk to the scientific and medical communities, policy makers, and the public.

More on the U54 SCORE program and ORHW-NIH

Organizational Tree